Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
107.9(c) 109.2(c) 109(c) 108.3(c) 108.4(c) Last
127 516 116 602 121 421 205 116 65 395 Volume
+1.22% +1.20% -0.18% -0.64% +0.09% Change
More quotes
Financials (EUR)
Sales 2018 28,1 M
EBIT 2018 -111 M
Net income 2018 -113 M
Finance 2018 331 M
Yield 2018 -
Sales 2019 59,7 M
EBIT 2019 -88,3 M
Net income 2019 -90,2 M
Finance 2019 174 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 111x
EV / Sales2019 54,9x
Capitalization 3 448 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the Proprietary Development and Partnered Discovery segments.The Proprietary Development segment combines proprietary research and development of therapeutic... 
Sector
Biotechnology & Medical Research
Calendar
08/01 | 10:00pmEarnings Release
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
07/12MORPHOSYS : Announces its Licensee Janssen has initiated a Phase 2/3 Program to ..
AQ
07/10MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (G..
AC
07/10MORPHOSYS : Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GA..
PU
07/10MORPHOSYS : Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GA..
EQ
07/04MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
07/02MORPHOSYS : I-Mab continues trend of large Chinese-led venture rounds
AQ
06/21MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/20MORPHOSYS : Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Mult..
AQ
06/19MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/15MORPHOSYS : Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic..
PU
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/11Johnson & Johnson, looking for its Tremfya niche, starts up new trial.. 
07/11$MOR: MorphoSys announces its licensee Janssen initiated Phase 2/3 Program (G.. 
07/10MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (G..
2
07/04MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the Ger.. 
06/21MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the Ger.. 
More tweets
Qtime:37
News from SeekingAlpha
06/20MorphoSys (MOR) Presents At The JMP Securities Life Science Conference - Slid.. 
05/31ALEXION PHARMACEUTICALS : Clinical Progress, Acquisitions And The Competition (P.. 
05/03MorphoSys AG's (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call T.. 
05/03MorphoSys AG 2018 Q1 - Results - Earnings Call Slides 
05/03MorphoSys AG reports Q1 results 
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 92,2 €
Spread / Average Target -15%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG41.55%4 029
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147